Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235625 · ClinicalTrials.gov registry record · Phase 2
Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00235625: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00235625 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00235625, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Turmeric (Curcuma Longa) is member of the ginger family and is best known for its culinary use as the major of component of curry powder. The volatile of oils (called curcuminoids) of the turmeric root, however, have anti-inflammatory actions which make them promising candidates for the treatment of psoriasis. For example, curcumin has been shown to improve psoriasis in experiments using in vitro models. Turmeric has been shown to have minimal side effects in doses up to 12 grams per day. The purpose of this study is to determine the safety and to estimate the efficacy of oral Curcuminoid C3 Complex® in patients with chronic psoriasis vulgaris.
Interventions
- DRUG Curcuminoids C3 Complex®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235625
The ClinicalTrials.gov registry entry for NCT00235625 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Curcuminoids C3 Complex® is the first listed.
NCT00235625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235625 about?
NCT00235625 is a clinical study titled "Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris". Turmeric (Curcuma Longa) is member of the ginger family and is best known for its culinary use as the major of component of curry powder. The volatile of oils (called curcuminoids) of the turmeric root, however, have anti-inflammatory actions which make them promising candidates for the treatment of...
What is the current status of trial NCT00235625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2005-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00235625?
The interventions under investigation include: Curcuminoids C3 Complex® (DRUG).
Who is sponsoring clinical trial NCT00235625?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.